Navigation Links
Drug dials down the energy within cells, UM researchers find

A drug effective at treating animal models of human autoimmune disorders and other diseases works by dialing down the activity of a key enzyme involved in energy production, University of Michigan researchers have found.

"Many drugs block the function of enzymes, essentially turning them off," said Gary Glick, who is the Werner E. Bachmann Collegiate Professor of Chemistry at U-M. "Our compound works more like a volume control, so we're able to dial enzyme activity down to a level that maintains normal function while simultaneously allowing for initiation of a process that selectively kills or disables disease-causing cells."

Glick and collaborators published their findings in the June 16 issue of ACS Chemical Biology.

The drug, discovered by Glick and coworkers and called benzodiazepine-423 (Bz-423), is a chemical cousin of anti-anxiety medications such as Valium and Xanax. In previous work, Glick's group showed that Bz-423 reduces effects of arthritis and the autoimmune disease lupus in mice and may be useful in treating psoriasis. Unlike conventional drugs for these conditions, which can't discriminate between healthy and disease-causing cells, Bz-423 is highly selective, homing in on disease-causing cells.

In an attempt to better exploit its therapeutic properties, the researchers have been studying the details of Bz-423's activity. They learned that the compound targets an enzyme inside mitochondria, the energy factories of cells. The specific enzyme, F1F0-ATPase, is responsible for producing most of the cell's ATP. That's a critical role because ATP, often referred to as the cell's energy currency, is the molecule that captures chemical energy from food and transfers it to energy-demanding processes, such as muscle contraction and the transmission of nerve signals.

"People had proposed in the past that if you could inhibit this enzyme, there might be therapeutic potential. But the problem is, if you inhibit the enzyme in the way most powerful drugs do, turning it off, you deplete the cell of ATP, and that's fatal," Glick said. "Our new work reveals the mechanism by which Bz-423 inhibits the enzyme while still allowing it to function. This is important because it suggests principles that may be useful for targeting other bioenergetic pathways. Now we have some rules that we can apply to be able to modulate the mitochondria in new ways that could be therapeutic."

Ultimately, the findings may have applications not only for lupus, arthritis and psoriasis, but also for other conditions, Glick believes. "There are other diseases---certain cancers and a number of other immune diseases---where we think the way the cells make and utilize energy is fundamental to the disease process. Combining that knowledge with our new knowledge of how to regulate the energy of the cell could open up new avenues for treating disease and monitoring the effectiveness of treatment."


'"/>

Source:University of Michigan


Related biology news :

1. Growth in biomass could put US on road to energy independence
2. Hydrogen and methane provide raw energy for life at Lost City
3. Study of energy and health in Africa focuses spotlight on charcoal and forest management
4. UCSD study clarifies insulins role in blocking release of energy in patients with type II diabetes
5. Ethanol and biodiesel from crops not worth the energy
6. Free-energy theory borne out in large-scale protein folding
7. Odd energy mechanism in bacteria analyzed
8. Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy
9. Lactic acid not athletes poison, but an energy source - if you know how to use it
10. Taking evolutions temperature: Researchers pinpoint the energy it takes to make a species
11. Johns hopkins researchers find link between cells energy use and genome health
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/14/2017)... 14, 2017  Wake Forest Baptist Medical Center today ... chief executive officer (CEO). Freischlag joins the medical center ... McConnell , M.D., who last year announced that he ... Center, after leading it since 2008.   ... Wake Forest Baptist,s academic health system, which includes Wake ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... ... February 22, 2017 , ... Kernel , a ... Systems, LLC (KRS) clinical development program. KRS is a neurotechnology spin-out from ... and clinical applications. The terms of the transaction were not disclosed. , ...
(Date:2/22/2017)... ... 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), ... today announced it has issued a scientific white paper entitled “Results from recent ... of commentaries from ProMIS’s scientific team offering insight into the Company’s product portfolio ...
(Date:2/22/2017)... DIEGO , Feb. 22, 2017 Aethlon ... the results of a study that validated the ability ... that are associated with increased mortality in immune-suppressed sepsis ... patients. The objective of the study ... of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex ...
(Date:2/21/2017)... ROCKVILLE, Md. , Feb. 21, 2017 Synthetic ... therapeutics designed to preserve the microbiome to protect and restore the ... for the year ended December 31, 2016 on Thursday, March 2, ... 4:30 p.m. EST. The dial-in information for the call is as ... ...
Breaking Biology Technology: